Thrombosis and Haemostasis 2025 Editors' Choice

This year's Editors' Choice highlights some of the most read and relayed 2025 publications in Thrombosis and Haemostasis. The selection reflects a growing emphasis on precision medicine, artificial intelligence (AI), and integrated care pathways in cardiovascular disease, along with continued insights into anticoagulation optimization, immune-thrombosis, platelet and neutrophil biology, as well as mechanisms behind thrombotic and bleeding disorders.

Publication History

Received: 03 December 2025

Accepted: 03 December 2025

Article published online:
02 January 2026

• References

• 1 Boriani G, Mei DA, Lip GYH. ARISTOTELES consortium. A European-multicenter network for the implementation of artificial intelligence to manage complexity and comorbidities of atrial fibrillation patients: the ARISTOTELES consortium. Thromb Haemost 2025; 125 (03) 189-193
• 2 Zhao Y, Cao LY, Zhao YX. Harnessing risk assessment for thrombosis and bleeding to optimize anticoagulation strategy in nonvalvular atrial fibrillation. Thromb Haemost 2024
• 3 Ortega-Martorell S, van Kempen E, Jouvent E, Tuladhar AM. The rise of the machines: using machine learning to assess thrombosis and bleeding risks, and optimizing anticoagulation strategies. Thromb Haemost 2025; 125 (05) 505-507
• 4 Ortega-Martorell S, Olier I, Ohlsson M, Lip GYH. TARGET Consortium. TARGET: a major European project aiming to advance the personalised management of atrial fibrillation-related stroke via the development of health virtual twins technology and artificial intelligence. Thromb Haemost 2025; 125 (01) 7-11
• 5 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2024; 124 (02) 135-148
• 6 Zheng Y, Li S, Liu X, Lip GY, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost 2023
• 7 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the “Atrial Fibrillation Better Care” pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
• 8 Romiti GF, Guo Y, Corica B, Proietti M, Zhang H, Lip GYH. mAF-App II trial investigators. Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mAFA-II randomized clinical trial. Thromb Haemost 2023; 123 (11) 1042-1048
• 9 Treewaree S, Lip GYH, Krittayaphong R. Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: win ratio analysis of the COOL-AF registry. Thromb Haemost 2024; 124 (01) 69-79
• 10 Krittayaphong R, Treewaree S, Yindeengam A, Komoltri C, Lip GYH. Latent class analysis for the identification of phenotypes associated with increased risk in atrial fibrillation patients: the COOL-AF registry. Thromb Haemost 2025
• 11 Chang H-C, Chan Y-H, Kuo L, Chao T-F. Patient care pathways and risk assessments in patients with atrial fibrillation: a comparison of Asian versus non-Asian cohorts. Thromb Haemost 2025; 125 (12) 1173-1180
• 12 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese expert consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
• 13 Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology Guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician's perspective. Thromb Haemost 2024; 124 (12) 1087-1094
• 14 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; 124 (09) 842-851
• 15 Kang DS, Yang PS, Kim D. et al. Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study. Thromb Haemost 2024; 124 (09) 883-892
• 16 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risks among patients with atrial fibrillation: an ecological epidemiological study comparing Korea and UK population. Thromb Haemost 2025; (e-pub ahead of print)
• 17 Tafur AJ, Brenner B, Demelo-Rodríguez P. et al; RIETE Investigators. Venous thromboembolism outcomes by geographic region and self-reported race: insights from the RIETE registry. Thromb Haemost 2025; (e-pub ahead of print)
• 18 Korompoki E, Heuschmann P, Harvey KH. et al; PRESTIGE-AF investigators. Prevention of stroke in intracerebral haemorrhage survivors with atrial fibrillation: rationale and design for PRESTIGE-AF trial. Thromb Haemost 2025; 125 (04) 395-403
• 19 Wu Y, Wang H, Wang Z. et al. Identifying risk factors for left ventricular thrombus in patients with ischemic left ventricular aneurysm using cardiac MRI. Thromb Haemost 2025; 125 (09) 908-915
• 20 Hashemi A, Bikdeli B. Navigating anticoagulation in ischemic left ventricular aneurysms: lessons from cardiac magnetic resonance imaging. Thromb Haemost 2025; 125 (09) 916-918
• 21 Nagao A, Goto S, Goto S. Antithrombotic therapy in people with hemophilia—a narrative review. Thromb Haemost 2025; 125 (11) 1060-1068
• 22 Shaw JR, Li N, Grussé M. et al. Influence of direct oral anticoagulant levels and thrombin generation on postoperative bleeding [SONAR]: a nested case-control study. Thromb Haemost 2025; 125 (12) 1226-1239
• 23 Choi Y, Jeong J, Heo K-N, Shin J, Lee J-Y. Major bleeding risk during concomitant use of antiarrhythmic drugs and oral factor Xa inhibitors: a nationwide self-controlled case series study. Thromb Haemost 2025
• 24 Kempers EK, Visser C, Geijteman ECT. et al; SERENITY consortium. Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease. Thromb Haemost 2025; (e-pub ahead of print)
• 25 Tao Y, Chen H, Dong C. et al; CURES investigators. Performance of bleeding risk scores for major bleeding in anticoagulated patients with pulmonary embolism: insights from the CURES Registry-2. Thromb Haemost 2025; (e-pub ahead of print)
• 26 Cassianni CE, McBane RD, Vlazny DT. et al. Venous thromboembolism outcomes among cancer and non-cancer patients managed with patient-centric guideline-driven protocol. Thromb Haemost 2025; (e-pub ahead of print)
• 27 Mauge L, Madar H, Carré J. et al; TITAN group of the French Society of Thrombosis and Haemostasis (SFTH). How to manage venous thromboembolism risk during pregnancy in patients with inherited antithrombin deficiency?. Thromb Haemost 2025; (e-pub ahead of print)
• 28 Zarghami M, Rashedi S, Piazza G, Gerhard-Herman MD, Barnes GD, Bikdeli B. Heterogeneity in American and European peripheral artery disease guidelines on non-statin lipid-lowering therapy and rivaroxaban. Thromb Haemost 2025; 125 (09) 821-824
• 29 Rosson M, D'Oria M, Simion C, Simioni P, Campello E. Critical review of international clinical practice guidelines recommendations for prevention, diagnosis, and management of central venous catheter thrombosis. Thromb Haemost 2025; (e-pub ahead of print)
• 30 van Dijk WJ, Kant AC, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis associated with different types of SARS-CoV-2 vaccines in the Netherlands—results of the TERA case-control study. Thromb Haemost 2025; (e-pub ahead of print)
• 31 Mai V, Jimenez D, Fergusson D. et al. Derivation and validation of a COPD-specific pulmonary embolism diagnostic strategy. Thromb Haemost 2025; (e-pub ahead of print)
• 32 Gando S, Wada T, Yamakawa K. et al. Utility of sepsis-induced coagulopathy among disseminated intravascular coagulation diagnostic criteria: a multicenter retrospective validation study. Thromb Haemost 2025; 125 (12) 1240-1248
• 33 Kaiser R, Gold C, Stark K. Recent advances in immunothrombosis and thromboinflammation. Thromb Haemost 2025; 125 (12) 1181-1194
• 34 Tong D, Gao Y, Sun W. et al. Neutrophil extracellular traps, platelets and endothelial cells cooperatively contribute to hypercoagulability in non-small cell lung cancer. Thromb Haemost 2025; 125 (10) 998-1009
• 35 Soltani F, Welman M, Samani SE, Pacis A, Lordkipanidzé M, Kaartinen MT. Factor XIII-A transglutaminase contributes to neutrophil extracellular trap (NET)-mediated fibrin(ogen) network formation and crosslinking. Thromb Haemost 2025; 125 (11) 1099-1114
• 36 De Moner B, Martinez-Sanchez J, Garrote M. et al. Endothelial damage in JAK2V617F myeloproliferative neoplasms with splanchnic vein thrombosis. Thromb Haemost 2025; 125 (10) 1010-1022
• 37 Pedersen NB, Münster AB, Lauridsen MM. et al. Association of fibrinogen variants with severity of obesity and metabolic liver disease: 2-year follow-up after bariatric surgery. Thromb Haemost 2025; (e-pub ahead of print)
• 38 Petito E, Guglielmini G, De Robertis E. et al; COVIR study investigators. Platelets from COVID-19 patients show an altered nitric oxide/reactive oxygen species production balance. Thromb Haemost 2025; 125 (07) 660-672
• 39 Zhang Z, Zhou X, Fang X, Zhou X, Cheng Z, Hu Y. Platelet disorders and medication strategies. Thromb Haemost 2025; (e-pub ahead of print)
• 40 Spagnolo M, Ammirabile N, Cutore L. et al. Changes in coagulation factor XI activity levels in patients with ST-segment elevation myocardial infarction undergoing primary PCI. Thromb Haemost 2025; 125 (09) 893-904
• 41 Spagnolo M, Capodanno D. Factor XI inhibitors for myocardial infarction: a safer path to thrombotic protection?. Thromb Haemost 2025; 125 (12) 1169-1172
• 42 Banaś A, Glanowski S, Ząbczyk M, Paszek E, Undas A. Elevated factor XI is associated with first and recurrent left atrial appendage thrombus of unknown origin. Thromb Haemost 2025; (e-pub ahead of print)
• 43 Pfeferman MB, Rashedi S, Lip GYH. et al. Lipoprotein(a) and venous thromboembolism: association, causality, and medications. Thromb Haemost 2025; 125 (11) 1069-1084